624 related articles for article (PubMed ID: 25003359)
1. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study.
Fu Y; Hao J; Zhang N; Ren L; Sun N; Li YJ; Yan Y; Huang D; Yu C; Shi FD
JAMA Neurol; 2014 Sep; 71(9):1092-101. PubMed ID: 25003359
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
3. Impact of an immune modulator fingolimod on acute ischemic stroke.
Fu Y; Zhang N; Ren L; Yan Y; Sun N; Li YJ; Han W; Xue R; Liu Q; Hao J; Yu C; Shi FD
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18315-20. PubMed ID: 25489101
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
5. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
6. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
7. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
9. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
[TBL] [Abstract][Full Text] [Related]
11. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
Zhu Z; Fu Y; Tian D; Sun N; Han W; Chang G; Dong Y; Xu X; Liu Q; Huang D; Shi FD
Circulation; 2015 Sep; 132(12):1104-1112. PubMed ID: 26202811
[TBL] [Abstract][Full Text] [Related]
12. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA; Weinstock-Guttman B
Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage.
Rolland WB; Lekic T; Krafft PR; Hasegawa Y; Altay O; Hartman R; Ostrowski R; Manaenko A; Tang J; Zhang JH
Exp Neurol; 2013 Mar; 241():45-55. PubMed ID: 23261767
[TBL] [Abstract][Full Text] [Related]
15. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
[TBL] [Abstract][Full Text] [Related]
16. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
17. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
[TBL] [Abstract][Full Text] [Related]
18. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
[TBL] [Abstract][Full Text] [Related]
19. Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial.
Lee SH; Park HK; Ryu WS; Lee JS; Bae HJ; Han MK; Lee YS; Kwon HM; Kim CK; Park ES; Chung JW; Jung KH; Roh JK
Eur J Neurol; 2013 Aug; 20(8):1161-9. PubMed ID: 23551657
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of reduced fingolimod dosage treatment.
Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]